Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$298.93

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $298.93 19

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $298.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.8512/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962533 CMS
Novartis Pharmaceuticals Corporation $19.4512/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310637 CMS
Organon LLC $13.0412/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178759 CMS
GlaxoSmithKline, LLC. $13.9011/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802010545 CMS
Organon LLC $5.3111/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178775 CMS
Janssen Biotech, Inc. $17.0811/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962535 CMS
AbbVie Inc. $21.5710/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796147023 CMS
AstraZeneca Pharmaceuticals LP $15.9710/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829625629 CMS
E.R. Squibb & Sons, L.L.C. $23.1708/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783527893 CMS
Novartis Pharmaceuticals Corporation $15.9008/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310633 CMS
Organon LLC $11.7308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837178767 CMS
Amgen Inc. $20.4306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221083 CMS
Janssen Biotech, Inc. $13.2106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962531 CMS
Janssen Biotech, Inc. $11.3605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962529 CMS
AbbVie Inc. $11.4304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796147021 CMS
Amgen Inc. $19.4604/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221091 CMS
Janssen Biotech, Inc. $12.5503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788962537 CMS
Amgen Inc. $21.7903/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825221087 CMS
GlaxoSmithKline, LLC. $16.7301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802522047 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,215.00 12/24/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1100762400
Principal investigator 1 Eli Lilly and Company $6,577.00 12/24/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1137363119
Principal investigator 1 ABBVIE INC. $36.00 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762052
Principal investigator 1 ABBVIE INC. $400.00 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762054
Principal investigator 1 ABBVIE INC. $6,215.00 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762056
Principal investigator 1 ABBVIE INC. $50.00 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762060
Principal investigator 1 ABBVIE INC. $2,500.00 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762062
Principal investigator 1 ABBVIE INC. $4,749.10 12/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100762064
Principal investigator 1 Janssen Research & Development, LLC $6,048.00 12/23/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999822
Principal investigator 1 ABBVIE INC. $4,199.80 12/19/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100761757
Principal investigator 1 Janssen Research & Development, LLC $1,975.00 12/19/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999826
Principal investigator 1 ABBVIE INC. $2,500.00 11/26/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 1100756493
Principal investigator 1 Eli Lilly and Company $28,956.00 11/25/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137354102
Principal investigator 1 Janssen Research & Development, LLC $5,883.00 11/25/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999832
Principal investigator 1 ABBVIE INC. $115.20 11/13/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100754971
Principal investigator 1 Eli Lilly and Company $14,438.00 11/12/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137364581
Principal investigator 1 ABBVIE INC. $2,640.60 11/07/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1100753661
Principal investigator 1 ABBVIE INC. $4,394.32 11/06/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100752257
Principal investigator 1 Eli Lilly and Company $2,603.10 10/28/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137353388
Recipient Eli Lilly and Company $2,455.00 10/15/2024 Covered Recipient Physician A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137346738
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 10/07/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999808
Principal investigator 1 Janssen Research & Development, LLC $1,513.00 09/27/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999840
Principal investigator 1 Eli Lilly and Company $2,247.69 09/25/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1137362843
Recipient Eli Lilly and Company $4,962.00 09/24/2024 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137346450
Recipient Eli Lilly and Company $913.00 09/24/2024 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137346736
Principal investigator 1 Janssen Research & Development, LLC $4,262.00 09/05/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999816
Principal investigator 1 Janssen Research & Development, LLC $2,154.00 09/02/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999828
Recipient Eli Lilly and Company $114.46 08/16/2024 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1137346448
Principal investigator 1 Janssen Research & Development, LLC $6,508.00 08/09/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999804
Principal investigator 1 ABBVIE INC. $115.20 08/07/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100735358
Principal investigator 1 ABBVIE INC. $252.16 08/01/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1100732848
Principal investigator 1 ABBVIE INC. $2,438.16 08/01/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100732854
Principal investigator 1 ABBVIE INC. $1,655.80 08/01/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1100732856
Principal investigator 1 ABBVIE INC. $115.20 07/30/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100731328
Principal investigator 1 ABBVIE INC. $3,600.00 07/30/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100731330
Principal investigator 1 Janssen Research & Development, LLC $1,488.00 07/29/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999812
Principal investigator 1 ABBVIE INC. $353.28 07/25/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100730860
Principal investigator 1 ABBVIE INC. $115.20 07/25/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100731024
Principal investigator 1 Eli Lilly and Company $2,799.89 07/24/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137363117
Principal investigator 1 ABBVIE INC. $238.08 07/18/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100730238
Principal investigator 1 ABBVIE INC. $1,179.00 07/15/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 1100729940
Principal investigator 1 ABBVIE INC. $700.00 07/15/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 1100729946
Principal investigator 1 Janssen Research & Development, LLC $17,759.00 07/11/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999810
Principal investigator 1 Janssen Research & Development, LLC $4,203.00 07/08/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999814
Principal investigator 1 ABBVIE INC. $2,491.00 07/03/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100725718
Principal investigator 1 ABBVIE INC. $517.12 07/03/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1100725798
Principal investigator 1 Janssen Research & Development, LLC $3,046.00 06/07/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999824
Principal investigator 1 ABBVIE INC. $727.36 06/05/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100721482
Principal investigator 1 ABBVIE INC. $250.00 05/09/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1100717220
Principal investigator 1 ABBVIE INC. $8,127.00 05/09/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1100717244
Principal investigator 1 ABBVIE INC. $3,609.76 05/08/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100716022
Principal investigator 1 Janssen Research & Development, LLC $6,602.00 05/06/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999806
Principal investigator 1 Janssen Research & Development, LLC $10,323.00 05/06/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999818
Principal investigator 1 Eli Lilly and Company $21.38 04/19/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1137363593
Principal investigator 1 Eli Lilly and Company $1,087.41 04/18/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1137354490
Principal investigator 1 Eli Lilly and Company $3,671.90 04/08/2024 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137370168
Principal investigator 1 Janssen Research & Development, LLC $12,973.00 04/05/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999838
Principal investigator 1 ABBVIE INC. $5,490.46 04/04/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100711118
Principal investigator 1 Janssen Research & Development, LLC $4,229.00 04/01/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999830
Principal investigator 1 Janssen Research & Development, LLC $12,970.00 03/28/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1078999820
Principal investigator 1 Eli Lilly and Company $286,902.00 03/25/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137356258
Principal investigator 1 ABBVIE INC. $115.20 03/14/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100708381
Principal investigator 1 Eli Lilly and Company $75,906.00 03/11/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1137355866
Principal investigator 1 Janssen Research & Development, LLC $4,738.00 03/11/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999834
Principal investigator 1 Eli Lilly and Company $2,500.00 03/05/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 1137363591
Principal investigator 1 Eli Lilly and Company $7,270.69 02/26/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137355610
Principal investigator 1 ABBVIE INC. $115.20 02/22/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100704740
Principal investigator 1 Eli Lilly and Company $2,788.75 02/13/2024 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137368646
Principal investigator 1 Eli Lilly and Company $311.35 02/08/2024 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137359203
Principal investigator 1 Eli Lilly and Company $7,294.00 02/06/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1137364583
Principal investigator 1 Janssen Research & Development, LLC $9,643.00 02/05/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1078999802
Principal investigator 1 ABBVIE INC. $356.56 02/01/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100701968
Principal investigator 1 Eli Lilly and Company $10,719.00 01/30/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137364585
Principal investigator 1 Janssen Research & Development, LLC $11,261.00 01/29/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1078999836
Principal investigator 1 Eli Lilly and Company $376.49 01/25/2024 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1137360309
Principal investigator 1 Eli Lilly and Company $2,267.21 01/25/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137363875
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,878.49 01/24/2024 Non-covered Recipient Entity
Christine Thai Md
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With SLE No dispute reported 06/30/2026 1123476540
Principal investigator 1 ABBVIE INC. $65.00 01/23/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100700910
Principal investigator 1 Eli Lilly and Company $16,885.00 01/22/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137364587
Principal investigator 1 Eli Lilly and Company $8,777.45 01/09/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353380
Principal investigator 1 Eli Lilly and Company $55,073.00 01/09/2024 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1137363873
Principal investigator 1 ABBVIE INC. $197.56 01/04/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1100697697
Principal investigator 1 Eli Lilly and Company $667,508.00 01/02/2024 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137355792